


№2<sup>Том5</sup>  
2017

# Фармакоэкономика

*теория и практика*



**Pharmacoeconomics**  
*theory and practice*

№2<sup>Volume5</sup>  
2017

- ❑ МЕТОДОЛОГИЧЕСКИЕ АСПЕКТЫ ПРОВЕДЕНИЯ ФАРМАКОЭКОНОМИЧЕСКОГО ИССЛЕДОВАНИЯ ТЕРАПИИ СПАСТИЧЕСКИХ ФОРМ ДЕТСКОГО ЦЕРЕБРАЛЬНОГО ПАРАЛИЧА
- ❑ МОДЕЛИРОВАНИЕ ВЫЖИВАЕМОСТИ В ФАРМАКОЭКОНОМИЧЕСКИХ ИССЛЕДОВАНИЯХ: МОДЕЛЬ МАРКОВА И МОДЕЛЬ РАЗДЕЛЁННОЙ ВЫЖИВАЕМОСТИ
- ❑ РЕЗУЛЬТАТЫ РОССИЙСКИХ ФАРМАКОЭКОНОМИЧЕСКИХ ИССЛЕДОВАНИЙ

## PHARMACOECONOMIC ANALYSIS OF COMBINATION OF DACLATASVIR AND SOFOSBUVIR IN TREATMENT OF CHRONIC HEPATITIS C (GENOTYPE 3) IN THE RUSSIAN FEDERATION: AMONG TREATMENT-EXPERIENCED PATIENTS

Kulikov A. Yu., Babiy V.V.

State Budgetary Educational Institution of Higher Professional Education "I.M. Sechenov First Moscow State Medical University" of the Ministry of Health of the Russian Federation, Moscow

**Abstract:** The objective of this study was to conduct cost-effectiveness analysis and budget impact analysis of antiviral drug treatment of chronic hepatitis C (peginterferon alfa + ribavirin 24 weeks (F0-F4), daclatasvir + sofosbuvir 12 weeks (F0-F3), daclatasvir + sofosbuvir + ribavirin 12 weeks (F4), sofosbuvir + ribavirin 24 weeks (F0-F4)) among treatment-experienced patients (HCV genotype 3). Both analyses were based on the developed pharmacoeconomic model (Markov model). Literature review showed absence of clear effectiveness data on using of peginterferon alfa + ribavirin in the targeted group therefore subsequent pharmacoeconomic analysis for this comparator was aborted. Obtained results showed that daclatasvir + sofosbuvir and daclatasvir + sofosbuvir + ribavirin was dominant in compares with sofosbuvir + ribavirin in the F0-F3 and F4 groups. In budget impact analysis total costs per one patient decreased on 283 623 rubles and 290 168 rubles in case of using daclatasvir + sofosbuvir instead of sofosbuvir + ribavirin among F0-F3 patients and daclatasvir + sofosbuvir + ribavirin instead of sofosbuvir + ribavirin among F4 patients, respectively.

**Key words:** chronic hepatitis c, genotype 3, cirrhosis, antiretroviral therapy, cost analysis, effectiveness analysis, cost-effectiveness analysis, budget-impact analysis.

### References

1. Ministry of health of the Russian Federation. State registry of medicines. [Internet]. URL: <http://grls.rosminzdrav.ru/> (Access date: 15.01.2017).
2. Pimenov N.N. [et al.]. Hepatitis C in Russia: epidemiological situation and pathways for development of diagnostics and monitoring // Epidemiology and infectious diseases. - 2012. - № 3 (4). - P. 4–10.

3. FBUN Central NII epidemiology Federal Service on customers' rights protection and human well-being surveillance - Monitoring center of viral hepatitis. HCV C registry. - Moscow, 2015.
4. Federal treasury. Consolidated information system of procurement [Internet]. URL: <http://zakupki.gov.ru/> (Access date: 12.12.2016).
5. AASLD. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. - 2016.
6. EASL. EASL Recommendations on Treatment of Hepatitis C 2016. - 2016.
7. Foster G.R. [et al.]. Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 Infection // Gastroenterology. - 2015. - № 6 (149). - P. 1462–1470.
8. Hilgenfeldt E., Schlachterman A., Firpi R.J. Hepatitis C: Treatment of difficult to treat patients // World J Hepatol. - 2015. - № 15 (7). - P. 1953–1963.
9. Leroy V. [et al.]. Daclatasvir, Sofosbuvir, and Ribavirin for Hepatitis C Virus Genotype 3 and Advanced Liver Disease: A Randomized Phase III Study (ALLY-3+) // Hepatology. - 2016. - № 5 (63). - P. 1430–1441.
10. Nelson D.R. [et al.]. All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study // Hepatology. - 2015. - № 61. - P. 1127–1135.
11. Zeuzem S., Dusheiko G., Salupere R. Sofosbuvir and ribavirin in HCV genotypes 2 and 3 // N Engl J Med. - 2014. - № 370 (21). - P. 1993–2001.
12. Federal State Statistic Service [Internet]. URL: <http://www.gks.ru/> (Access date: 14.11.2016).